Fisher & Paykel (NZX:FPH): Which are its key markets and products?

Be the First to Comment Read

Fisher & Paykel (NZX:FPH): Which are its key markets and products?

NZX Healthcare Stocks
Image source: Photo by RODNAE Productions from Pexels


  • Fisher & Paykel delivered an operating revenue of $900 million in H1 FY22, down 1% on pcp. 
  • The Group has 2 product groups - the Hospital and the Homecare product group.
  • FPH produced 36% of its revenue from North America and 30% from the Asia Pacific region in H1 FY22.

Fisher & Paykel Healthcare Corporation Limited (NZX:FPH; ASX:FPH) creates, manufactures and markets products and systems that are used for respiratory care, surgery, etc. 

The Group’s products are structured in two parts, namely the Hospital and the Homecare group.

FPH’s details
Image source: © 2021 Kalkine Media®, Data source- Refinitiv

The Hospital product group involves products used in invasive ventilation, non-invasive ventilation, nasal high-flow therapy, and laparoscopic and open surgery.  

ALSO READ: What is Fisher & Paykel’s (NZX:FPH) stance for the rest of FY22? 

These products not only help healthcare providers in enhancing patient results but also provide economic benefits by reducing the need to increase care and patient stays in hospital. 

The other product group is homecare that includes devices and systems used to cure obstructive sleep apnea (OSA) and offer respiratory support at homes. These consist of FPH’s CPAP therapy masks and flow creators, data management tools and interfaces. 

FPH’s performance across products group 

FPH’s first half of FY22 has continued to be strong with the Group delivering an operating revenue of $900 million for the period. The Group witnessed increased demand for most of its hospital products amid a surge in COVID-19 cases globally. 

Must Read: Which are 10 major healthcare companies trading on NZX? 

While the hospital product group accounted for 74% of FPH’s operating revenue, the homecare product group generated 25% of the Group’s revenue for the 6 months ended 30 September 2021. Hospital hardware sales dropped 10% for the first half while sales for hospital consumables rose 24% on pcp in constant currency. 

FPH generated an operating revenue of $670.2 million and $226.9 million from the hospital product group and the Homecare product group, respectively, in 1HFY22. 

Global performance 

FPH’s largest markets by revenue are North America, Europe and the Asia Pacific. 

Fisher generated 36% of its revenue from North America, 26% from Europe, 30% from the Asia Pacific and 8% from other global markets for the 6 months ended 30 September 2021. 

Related Read: What is Fisher & Paykel’s (NZX:FPH)  outlook for the remaining FY22 period? 

FPH also launched the Visairo mask for non-invasive ventilation in the US in August. The Group also launched the Evora Full mask for OSA in NZ and Australia in October. 

Shares of Fisher & Paykel gained 0.46% in trading on Wednesday to close at $33.

Bottom Line 

Fisher plans to invest nearly $700 million over the next 5 years to maintain its extra manufacturing and distribution capacity to scale up faster. 

(NOTE: Currency is reported in NZ Dollar unless stated otherwise) 


Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK